Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
12
1
1
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
8.3%
1 terminated/withdrawn out of 12 trials
80.0%
-6.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Dapagliflozin With or Without Spironolactone for HFpEF
Role: collaborator
Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy
Role: lead
Effectiveness of Digital Rehabilitation (SIMPLI.REHAB) in Hand Arthritis
Role: lead
Pulmonary Embolism Registry
Role: collaborator
Impact of the Save the Shame! Game on Advanced Life Support Knowledge
Role: lead
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
Role: collaborator
Preparation Regimens to Improve Capsule Endoscopy Visualization and Diagnostic Yield
Role: lead
Acute and Long-term Impact of Cancer Treatment on Head and Neck Cancer Patients: FIT4TREATMENT
Role: collaborator
Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3
Role: lead
Biomarkers of Thrombosis as Predictors of Venous Thromboembolism Risk in Cancer Patients
Role: lead
Walking Football as a Supportive Medicine for Patients With Prostate Cancer
Role: collaborator
Influence of EPICardial Adipose Tissue in HEART Diseases: EPICHEART Study
Role: lead
All 12 trials loaded